Original Article | Published:

Functional expression of opioid receptor-like receptor and its endogenous specific agonist nociceptin/orphanin FQ during mouse embryogenesis

Abstract

Expression of opioid receptor-like receptor (ORL1) and its endogenous peptide agonist nociceptin/orphanin FQ (N/OFQ) during mouse embryogenesis have been investigated. Transcripts of ORL1 and N/OFQ were detected by RT-PCR in mouse brain of day 8 embryo (E8) and the expression continued afterwards. Northern blot analysis revealed abundant expression of ORL1 at postnatal day 1 (P1) and N/OFQ at E17 and P1 in the brain but none was detected in other embryonic tissues. The presence of functional ORL1 in mouse embryonic brain was also confirmed by specific binding of [3H] N/OFQ (kd=l.3 ± 0.5 nM and Bmax = 72 ± 9 fmol/mg protein) as well as by N/OFQ-stimulated G protein activation.

Introduction

Opioid receptors belong to the G-protein-coupled receptor family that is characterized by the seven transmembrane spanning domains in structure. Three subtypes of the opioid receptors (μ, δ, and κ) have been cloned and characterized through their distinct affinities for different opioid ligands. These opioid receptors are all coupled to the inhibitory G protein (Gi) and negatively regulate adenylate cyclase1. Opioid receptor-like receptor (ORL1), a new member of this family of G-protein coupled receptors, has been cloned from brain recently, which shares high homology in sequence with other opioid receptors2, 3, 4, 5, 6, 7, 8. ORL1 binds to previously identified opioid peptides with poor affinity, and its endogenous specific agonist nociceptin/orphanin FQ (N/OFQ) has just been identified9, 10. Data from our and other laboratories have demonstrated that in neuronal cells, N/OFQ inhibits forskolin-stimulated cAMP accumulation, stimulates activation of pertussis toxin-sensitive G proteins11, 12, 13, and increases inwardly rectifying K+ conductance14. Behavioral studies demonstrate that N/OFQ, unlike other opioids, produces hyperalgesic effect10 and even functionally antagonizes the antinociceptive effect of other opioids15, 16. It was lately found that ORL1-knock-out mice display hearing impairment17. However, information on the expression of ORL1 and N/OFQ during mouse embryonic development is lacking. In the present study, we have demonstrated that both ORL1 and N/OFQ express in mouse embryonic brain but not in other tissues and that N/OFQ stimulation leads to activation of inhibitory G proteins.

Materials and Methods

Animals

Pregnant female Balb/c mice on embryonic days 8, 10, 14, 17, 19 (E8, E10, E14, E17, E19), postnatal day 1 (P1) mice and adult mice were obtained from the Animal House of Shanghai Institute of Cell Biology. All animals were sacrificed with the use of cervical dislocation following the Guideline for the Care and Use of Animals approved by the Institute.

Isolation of total RNA

50-100 mg of tissue was homogenized in 1 ml of TRIzol Reagent (Gibco-BRL) using a glass homogenizer. Total RNA was extracted according to the manufacturer-provided protocols and dissolved in diethypyrocarbonate (DEPC) treated water. The amount of total RNA was determined by absorbence at 260 nm.

Reverse transcription polymerase chain reaction(RT-PCR)

First-strand cDNA was made from total RNA by using Superscript preamplifiaction system (Gibco-BRL) and following the procedures suggested by the manufacturer. 2 μg of total RNA and 0.5 μg of oligo (dT)12–18 was heated to 70 °C for 10 min in 11 μl of DEPC-treated water. 4 μl of 5× synthesis buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl2), 1 ml of 10 mM dNTP mix, 2 μl of 0.1 M DTT, 1 μl of RNasin (20U/μl) and 1 μl of reverse transcriptase (SuperScript II RT; 200U/μl) were added to the sample, and then incubated the samples at 42 °C for 1 h. The reaction was terminated by incubating the mixture at 70 °C for 10 min18.

PCR primers used were ORT5 (IndexTermIndexTermGGGATCTCCACCAGGCACTCGATC) and ORL1REcoR (IndexTermIndexTermCAGGAATTCCATGGGCAGGTCCACGCCTAGTC) for ORL1; OFQ5 (IndexTermIndexTermACTGCCTCACCTGCCAGG) and OFQ3 (IndexTermIndexTermGGCTCCTTCTGGCTACAC) for N/OFQ. ORT5/ORL1 REcoR primers correspond to regions from bases 497 to 515 and 1293 to 1310 on human ORL1 cDNA2 respectively and are conserved among rat, mouse and human. OFQ5/OFQ3 primers were correspond to regions from bases 31 to 47 and 502 to 518 on rat N/OFQ precursor cDNA9 respectively. The PCR reactions (50 μl) contained 5 μl of first-strand cDNA, 2 units of Taq polymerase (Promega). The conditions used were: 94 °C for 1 min; 60 °C for 1 min; 72 °C for 1.5 min. This cycle was repeated 30 times. The PCR products ( 800 bp and 480 bp respectively) were analyzed on a 1% agarose gel.

Northern blot analysis

Total RNA of each sample was electrophoresed on a 1% agarose-glyoxal gel (30 μg/lane except lane 1 was 10 μg), transferred onto a nylon membrane (Amersham) with 20 × SSC (1 × SSC is 0.15 M Sodium Chloride, 0.15 M Sodium Citrate, pH 7.0). Then the membrane was exposed to UV light using a GS Gene Linker (Bio-Rad).

The 1150 bp restriction fragment containing entire coding region of ORL1 was released from plasmid pcDNA3:hORL118, purified using QIAEX Gel Extraction Kit (QIAEX), and used as ORL1 probe. N/OFQ probe was the 480 bp PCR product of OFQ5/OFQ3 purified using QIAEX Gel Extraction Kit. 32P-labeled random-primed probes were made to a specific activity of 5 × l08 dpm/g DNA using the Ready To Go DNA Labeling Kit (Pharmacia Biotech).

The membrane was perhybridized in 0.5 M phosphate buffer (pH 7.2), 7 % Sodium Dodecyl Sulfate (SDS), 1 mM EDTA at 65 °C for 4 h, and hybridized to 32P-labeled probe at 65 °C for 20 h19. The membrane was washed twice in 2 × SSC/0.1% SDS at room temperature for 15 min each, and then twice in 0.5 × SSC/0.1% SDS at 55 °C for 15 min each. The membrane was exposed to X-ray film (Kodak) for 5-7 days.

N/OFQ binding assay

Mouse embryonic brain membranes were prepared by homogenizing the embryonic brain in 1 ml of lysis buffer containing 5 mM Tris-HCl (pH 7.5), 5 mM EDTA, and 5 mM EGTA and the membrane lysate was centrifuged at 3000 × g at 4 °C for 15 min. Then the supernatant was centrifuged at 30,000 × g at 4 °C for 30 min. Pellets were solubilized in buffer containing 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, and 5 mM EGTA. The binding assay was carried out basically as described11. Aliquot with different concentrations (2.0 11.0 nM) of [3H] N/OFQ (39 Ci/mmol, Phoenix Pharmaceuticals, Inc, CA) in a total volume of 0.2 ml were incubated at 30 °C for 60 min. The reaction was terminated by diluting with cold phosphate-buffered saline and filtered through glass fiber filters under vacuum. Bound radioactivity was measured by liquid scintillation counter (Beckmann Instruments, Torrance, CA). Nonspecific binding was measured in the presence of 100 mM etorphine (Sigma). Equilibrium binding data were analyzed using the curve-fitting program LIGAND. Protein content of each sample was determined as described above.

[35S]GTPS binding assay

The assay was carried out as described11, 20. Embryonic brain membranes were prepared as above. The membrane (containing 12 μg protein) in 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM DTT, 100 mM NaCl, 40 μM GDP, and 0.5 nM [35S]GTPγ S (1200 Ci/mmol, DuPont-New England Nuclear) in the presence or absence of N/OFQ, [D-Ala2, MePhe4, Gly-ol5] enkephalin (DAGO)(Sigma), or UK14304 (Sigma) in a total volume of 100 μl were incubated at 30 °C for 60 min. The reaction was terminated by adding 4 ml phosphate-buffered saline and then immediately filtered through GF/C filters under vacuum. The filters were washed and counted by liquid scintillation counter. Data were means of duplicate samples. Basal binding was determined in the absence of agonist and non-specific binding was obtained in the presence of 10 mM GTPγ S. The percentage of stimulated [35S]GTPγ S was calculated as 100 × (cpmsample − cpmnonspecific) /(cpmbasal − cpmnon-specific).

Results and Discussion

Expression of ORL1 and N/OFQ during development

In situ hybridization and immunohistochemistry studies revealed that ORL1 and its endogenous ligand N/OFQ express widely over the brain3, 4, 6, 9, 21, 22. ORL1 transcripts are present in the CNS, including the hypothalamus, brainstem and spinal cord dorsal horn1, 7, 8. ORL1 also expresses in a few peripheral organs such as intestine, vas deferens and spleen6. It suggests that ORL1 plays a role in many central processes, including learning and memory. Transcripts of N/OFQ precursor protein was detected during mouse embryogenesis23. However, the expression of ORL1 in embryogenesis has not been reported. Therefore, we examined the expression of ORL1 and N/OFQ in mouse brains on various embryonic days (E8, E10, E14, E17, E19) and postnatal day 1 (P1) as well as in adult mouse brain. To detect ORL1 receptor mRNA sensitively, we measured the levels of ORL1 and N/OFQ transcripts with RT-PCR and Northern blotting. As shown in Fig 1A and B, with the primer sets of ORT5/ORL1REcoR and OFQ5/OFQ3, PCR products of expected sizes (800 bp and 480 bp) were detected in brain samples from E10 to adult mice (Lanes 3-8). PCR reactions using embryonic brain RNA (without reverse transcription Fig 1C) and the cDNA form other embryonic tissues (kidney, liver, heart) as template failed to produce any detectable PCR product (data not shown). β-actin was used as a positive internal control in PCR ( 380bp). The quantitative densitometry analysis show from mouse E10 to E19, the amounts of RT-PCR products (relative to the product of β-actin used as an internal control) of ORL1 and OFQ increased and they maintained the similar levels since E19. The above results indicate that the transcripts for ORL1 and N/OFQ are present in embryonic, postnatal and adult mice brains.

Figure 1
figure1

Embryonic expression of ORL1 and N/OFQ mRNA in mouse brain detected by RT-PCR. The expression was assayed by RT-PCR for ORL1 using primer pair of ORL5/ORL1REcoR (A) and for N/OFQ using primer pair of OFQ5/OFQ3 (B). As control, the total RNA was used as the PCR template without RT reaction, using primer pair of ORL5/ORL1REcoR and OFQ5/OFQ3 (C). Internal controls of actin was included in each PCR reaction and the actin products were shown as a band of 380 bp. Lane 1: DNA markers, lane 2:E8 (0.3; 0), lane 3: E10 (1.0; 0.1), lane 4:E14 (2.7; 0.9), lane 5:E17 (5.1; 0.95), lane 6:E19 (9.8; 0.90), lane 7: P1 (9.9; 0.92), lane 8: adult (9.5; 1.1). In each lane, the amount of PCR product determined by densitometer relative to internal control β-actin was indicated in parentheses (A; B).

In Northern analysis, ORL1 and N/OFQ transcripts were detected only in embryonic and postnatal mice brains, not in other embryonic and postnatal tissues. For ORL1, P1 brain contains a RNA species of 3.7 kb, hybridizable to the ORL1 cDNA probe (Fig 2A, lane 3), but ORL1 transcripts were not detectable in E17 under the same conditions (Fig 2A, lane 2). For N/OFQ, a RNA species of 1.3 kb were detected (Fig 2B, lane 2, 3) in both E17 and P1 brain.

Figure 2
figure2

Northern analysis of ORL1 (A) and N/OFQ (B) mRNA transcripts. Lane 1: CHO-ORL1 cells; lanes 2 and 3, brain; lanes 4 and 5, kidney; lanes 6 and 7, liver; lanes 8 and 9, heart. Lanes 2, 4, 6, 8: E17; lanes 3, 5, 7, 9: P1. (C) Ethidium bromide staining of the gel before Northern blotting.

The results of RT-PCR and Northern analysis indicate that the transcripts of ORL1 and N/OFQ are present on and after E10. Nothacker et al reported that the OFQ precursor mRNA was detected in fetal human brain and kidney but not in adult human kidney by Northern analysis24. In present study, the expression of OFQ did not been detected in mouse E17 and P1 kidney. This could be a result of the samples used in different species and/or different embryonic stages. In μ receptor-deficient mice, some unexpected changes in sexual function in male homozygotes were observed, such as reduced mating activity, a decrease in sperm count and motility, and litter size25. These data suggest that opioid receptor may play an important role in development. Other reports confirmed that N/OFQ mRNA was detected in mouse brains of embryonic day 14, and larger amounts were detected on postnatal day 1. Then the levels of mRNA decreased gradually as mouse grew23.

Membrane fractions were prepared from E17 brain, and the presence of ORL1 receptors was examined using [3H] N/OFQ, a specific agonist of ORL1. As shown in Fig 3A, binding of N/OFQ to embryonic brain membranes was specific and saturable. Analysis of saturation binding data indicates a dissociation constant kd of 1.3 ± 0.5 nM and Bmax of 72 ± 9 fmol/mg protein, comparable to the value obtained in rat brain homogenates26 and in neuroblastoma cells11, 13. These data are consistent with our RT-PCR and Northern results and confirm that the gene product of ORL1 is expressed on cell membranes of embryonic brain.

Figure 3
figure3

Functional expression of ORL1 in mouse embryonic brain. (A) Saturation binding of [3H]-labeled N/OFQ to ORL1 receptor. The membrane preparations were incubated with various concentration of [3H] N/OFQ and the [3H]N/OFQ bound was determined. (B) [35S]GTP γ S binding assay: Assays were performed in the presence of 10 mM N/OFQ, 10 μM DAGO, or 10 μM UK14304 respectively, at 30 °C for 60 min. Data were means ± standard error of two independent experiments performed in duplicate.

ORL1-mediated G protein activation

[35S]GTP-γS binding is an effective method to probe gonist-dependent activation of G proteins. Using this method, the activation of pertussis toxin (PTX)-sensitive G proteins after agonist occupation of opioid27, muscarinic28, 29, α 2-adrenergic plasma membrane-bound receptors have been determined13. We have observed that ORL1 receptor was expressed on mouse embryonic brain membranes. Therefore, we took on to determine the activation of the inhibitory G-protein mediated by ORL1 in embryonic brain using [35S]GTPγ S binding. As shown in Fig 3B, activation of μ opioid receptor by DAGO and α2-adrenergic by UK14304 increased [35S]GTPγ S binding 10 - 30 %, however, in strong contrast, stimulation of 10 mM N/OFQ caused an 100 % increase in [35S]GTPγ S binding to the membranes from embryonic brain. These data confirm the expression of ORL1 in embryonic brain and indicate that ORL1 is functionally coupled to G protein. The results also suggest that ORL1 may be present in embryonic brain more abundant than μ opioid receptors, or alternatively, it may couple to G protein more efficiently than μ opioid receptor in fetal brain. Experimental data have shown that ORL1 and μ opioid receptor mediate opposite effects in pain modulation9, 10. Changes in sexual functions such as reduced mating activity, decreases in sperm count and motility, and litter size have been observed in male homozygotes of μ receptor-knock-out mice25. These results suggest that opioid receptor may play a role in development. The differential activities in G protein activation mediated by these two important receptors may therefore have developmental significance.

In summary, we have demonstrated that ORL1 and N/OFQ is functionally expressed in mouse embryonic brain. RT-RCR and Northern analysis indicate the presence of ORL1 and N/OFQ transcripts in mouse embryonic brain. [3H]N/OFQ bound to the embryonic brain membranes specifically. Binding of the receptor with its specific agonist N/OFQ activated inhibitory G protein as indicated by stimulation of [35S]GTPγ S binding.

References

  1. 1

    Reisine T . Opiate receptors. Neuropharmacology 1995; 34:463–72.

  2. 2

    Mollereau C, Parmentier M, Mailleux P . et al. ORL1, a novel member of the opioid receptor family Cloning, functional expression and localization. FEBS Letters 1994; 341:33–8.

  3. 3

    Fukuda K, Kato S, Mori K, et al. cDNA cloning and regional distaaribution of a novel member of the opioid receptor family. FEBS Letters 1994; 343:42–6.

  4. 4

    Chen Y, Fan Y, Liu J, et al. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Letters 1994; 347:279–83.

  5. 5

    Bunzow JR, Saez C, Mortrud M, et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ or κ opioid receptor type. FEBS Letters 1994; 347:284–8.

  6. 6

    Wang JB, Johnson PS, Imai Y . DNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Letters 1994; 348:75–9.

  7. 7

    Wick M J, Minnerah SR, Lin X, Elde R, Law PY and Loh HH . Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned μ, δ and κ opioidreceptors Mol Brain Res 1994; 27:37–44.

  8. 8

    Lachowicz JE, Shen Y, Monsma F J, Jr, and Sibley DR . Molecular cloning of a novel G protein-coupled receptor related to the opioid receptor family. J Neurochem 1995; 64:34–40.

  9. 9

    Meunier JC, Mollereau C, Toll L . Isolation and structure of the endogenous agonist of opioidreceptor-like ORL1 receptor. Nature 1995; 377:532–5.

  10. 10

    Reinscheid R, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates anopioid-like G protein-coupled receptor. Science 1995; 270:792–4.

  11. 11

    Cheng Z, Fan GH, Zhao J, et al. Endogenous opioid receptor-like receptor in human neu-roblastoma SK-N-SH cell: activation of inhibitory G protein and homologous desensitization.Neuroreport. 1997; 8:1913–8.

  12. 12

    Connor M, Yeo A, Henderson G . The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line. Br J Pharmacol 1996; 118:205–7.

  13. 13

    Ma L, Cheng Z, Fan GH, Cai YC, Jiang LZ, Pei G . Functional expression, activation and desensitization of opioid receptor-like receptor ORL1 in neuroblastoma × glioma NG 108 – 15 ybrid cells. FEBS letter 1997; 403:91–4.

  14. 14

    Vaughan CW, and Christie MJ . Increase by the ORL1 receptor (opioid receptor-like 1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones. Brit J Pharmacol. 1996; 117:1609–11.

  15. 15

    Mogil JS, Grisel JE, Zhangs G, Belknap JK, Grandy DK . Functional antagonism of μ, δ,κ opioid antinociception by orphanin FQ. Neurosci-Lett 1996; 214:131–4.

  16. 16

    Rossi GC, Leventhal L, Pasternak GW . Naloxone sensitive orphanin FQ-induced analgesia in mice. Eur-J-Pharmacol 1996; 12:311, R7–8.

  17. 17

    Nishi M, Houtani T, Noda Y, et al. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphanin FQ receptor. EMBO J 1997; 16:1858–64.

  18. 18

    Wu YL, Pu L, Ling K . et al. Molecular characterization and functional expression of opioidreceptor-like1receptor. Cell Research 1997; 7:69–77.

  19. 19

    Church and Gilbert . Genomic sequencing. Proc Natl Acad Sci USA 1984; 81:1991–5.

  20. 20

    Tian WN, Duzic E, Lanier SM, and Deth RC . Determinants of α2-adrenergic Receptor Activation of G Proteins: Evidence for a Precoupled Receptor/G Protein State Mol Pharmacol 1993; 45:524.

  21. 21

    Anton B, Fein J, To T, Li X, Silberstein L, and Evens C . Immunohistochemical localization of ORL1 in the central nervous system of the rat. J Comp Neurol 1996; 368:229–51.

  22. 22

    Houtani T, Nishi M, Takeshima H, Nukada T, and Sugimoto T . Structure and regional distribution of nociceptin/orphanin FQ precursor. Biochem Biophys Res Comm 1996; 219:714–9.

  23. 23

    Saito Y, Maruyama K, Kawano H, et al. Molecular cloning and characterization of a novel form of neuropeptide gene as a developmentally regulated molecule. J Biol Chem 1996; 271:15615–22.

  24. 24

    Nothacker HP, Reinscheid RK, Mansour A . Primary structure and tissue distribution of the prphanin FQ precursor. Proc Natl Acad Sci USA 1996; 93:8677–82.

  25. 25

    Tian BM, Broxmeyer HE, Fan Y . Altered hematopoiesis, behavior, and sexual function in μ opioid receptor-deficient mice. J Exp Med 1997; 185:11517–22.

  26. 26

    Dooley CT, Houghten RA . Orphanin FQ: receptor binding analog structure activity relationships in rat brain. Life-Sci 1996; 59:PL23–9.

  27. 27

    Traynor JR, Nahouaki SR . Modulation by μ -opioid agonists of guanosine-5-O-3(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1995; 47:848.

  28. 28

    Hilf G, Gierschik P, Jakobs KH . Muscarinic acetylcholine receptor-binding of 5-O-(3-thio-triphosphate) to guanine nucleotide binding proteins in cardiacmembranes. Eur J Biochem 1989; 186:725–31.

  29. 29

    Lazareno S, Farries T, Birdsall NJM . Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected human muscarinic receptors m1-m4. Life Sci 1993; 52:449–56.

Download references

Acknowledgements

This research was supported by research grants from National Natural Science Foundation of China (39630130 and 39625010), Chinese Academy of Sciences (KY951-A1-301-01-05), Shanghai Educational Development Foundation, and the German Max-Planck Society. The authors thank Yan Ping WANG and Ping WANG for their help.

Author information

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • Opioid receptor-like receptor (ORL1)
  • nociceptin/orphanin FQ (N/OFQ)
  • mouse embryogenesis
  • functional expression

Further reading